COMMUNIQUÉS West-GlobeNewswire
-
Financial Calendar 2018/19
28/08/2018 - 10:44 -
Transactions in relation to share buyback program
28/08/2018 - 10:26 -
Aino Health AB (publ): Aino Health signs agreement with Sjuksyrra AB
28/08/2018 - 09:01 -
GENFIT: Major Milestone achieved with full recruitment of the Phase 2 trial evaluating elafibranor in PBC
28/08/2018 - 08:03 -
GENFIT : étape importante franchie avec la fin du recrutement des patients de l'essai de Phase 2 évaluant elafibranor dans la PBC
28/08/2018 - 08:03 -
GW Pharmaceuticals presents latest cannabidiol oral solution (CBD) data at the 13th European Congress of Epileptology
28/08/2018 - 08:00 -
ObsEva SA to Participate in September Investor Conferences
28/08/2018 - 07:30 -
MDxHealth (R): SelectMDx Cost-effective in Four European Countries
28/08/2018 - 07:06 -
MDxHealth (R) :
28/08/2018 - 07:06 -
MDxHealth (R): SelectMDx Cost-effective in Four European Countries
28/08/2018 - 07:01 -
MDxHealth (R) : SelectMDx : rapport coût-effectivité positif dans quatre pays européens
28/08/2018 - 07:01 -
Biocartis Group NV: Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy
28/08/2018 - 07:01 -
Kiadis Pharma to attend upcoming investor conferences in September 2018
28/08/2018 - 07:01 -
Orphazyme announces Interim Report First Half 2018
28/08/2018 - 07:01 -
Wright Medical Group N.V. Announces Pricing of Public Offering of Ordinary Shares
28/08/2018 - 01:42 -
EB Research Partnership and EB Research Foundation Join Forces to Advance Breakthroughs in Epidermolysis Bullosa Research
28/08/2018 - 01:00 -
Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema
27/08/2018 - 23:14 -
Veritas Completes Share Purchase Agreement with 3 Carbon Extractions Inc.
27/08/2018 - 22:59 -
Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA
27/08/2018 - 22:30
Pages